Buried treasure
Transcript of Buried treasure
© 2002 Macmillan Magazines Ltd154 | MARCH 2002 | VOLUME 2 www.nature.com/reviews/cancer
H I G H L I G H T S
What determines whether colorectal cancer willrecur after surgery? Duke’s system forhistopathological staging has been the mainstay ofcolorectal cancer prognosis for many years. Butpatients with tumours of the same Duke’s stage canhave radically different outcomes.
Now, in the 19 January issue of The Lancet, BertVogelstein’s group describe a new molecular techniquecalled ‘digital single-nucleotide polymorphism’ (SNP),which they use to see how allelic imbalance ofchromosomes 8p and 18q within tumour cells relatesto disease progression. These chromosomes havepreviously been shown to exhibit allelic imbalance incolorectal cancer, but their relevance to diseaseprogression is not understood.
The first step is to find an informative SNP onthese chromosomes — one for which the patient isheterozygous — using DNA purified from normaltissue at the tumour margin. Once an informativemarker has been found, purified DNA frommicrodissected tumour tissue is plated out roboticallyin 384-well plates at low concentrations, so that anaverage of one molecule containing the SNP lands ineach well. After polymerase chain reaction (PCR)amplification, fluorescent probes that can distinguishthe two alleles are used to count each allele one byone. Statistical algorithms are then used to determinewhether there is an allelic imbalance in the sample. Bythis mechanism, the proportion of each allele in apatient’s DNA can be assessed. This technique is moreaccurate than traditional methods of measuringallelic imbalance, which use microsatellite markers, inpart because the PCR products obtained are identicalin size, eliminating any artefacts caused bypreferential degradation of larger alleles.
The authors studied 180 patients who had early-stage sporadic colorectal cancer with no sign ofmetastases. Digital SNP was used to test for imbalances
of chromosomes 8p and 18q in surgically removedtumours. Tumour samples were divided into thosewith allelic imbalances in both chromosomes, thosewith imbalances in either (but not both) chromosome,and those that showed no imbalance at all on eitherchromosome. The five-year disease-free survival wasremarkably different in the three groups: 100%, 74%and 58% in tumours with no allelic imbalance,imbalance in one chromosome, and imbalance in bothchromosomes, respectively. These results wereindependent of other variables, including Duke’s stage.So, a higher allelic imbalance correlates with a lowerprobability of disease-free survival.
How, then, does allelic imbalance affect prognosis?The authors propose three models. First, importanttumour-suppressor genes on chromosomes 8p and 18qare lost. Second, allelic imbalance in thesechromosomes might simply reflect instability withinthe cell as a whole. And third, if all colorectal cancersaccumulate allelic imbalances at similar rates, allelicimbalance would simply represent a measure of howlong the tumour has existed.
Although the authors do not favour a particularmodel, previous studies have correlated allelicimbalances in at least nine chromosomes withprognosis in colorectal cancer, which indicates thataneuploidy in general, rather than loss of specifictumour suppressors, might drive tumour progression.Similar correlations have been made for other cancers.So perhaps we’ll eventually be able to use the samedigital SNP-based assay to predict outcomes in everycancer patient.
Sandra Clark
References and linksORIGINAL RESEARCH PAPER Zhou, W. et al. Counting alleles to predictrecurrence of early-stage colorectal cancers. Lancet 359, 219–225 (2002)WEB SITEBert Vogelstein’s lab:http://www.hhmi.org/research/investigators/vogelstein.html
Countdown to recurrence
P R O G N O S I S
Buried treasure
• http://www.cancer.gov/
It’s all-change at the UnitedStates National CancerInstitute (NCI): as well as anew Director, it has a newweb site.
Navigation is now througha series of index tabs; thisprovides a welcome air ofconsistency throughout thesite, but it’s not obviouswhich information isdirected at researchers andwhich is aimed at thegeneral public. Forresearchers, finding fundingopportunities isstraightforward: the‘Research funding’ tabtakes you to a well-organized list ofannouncements andcontact persons for grantapplications. The ‘Researchprograms’ section isredundant with ‘About NCI’,but both sections provide areasonable overview of NCI-funded research.
The problems come whenyou want to find a particularinvestigator or resource. Theresearcher directory is nowhidden under ‘Organizationalstructure’ in ‘About NCI’, andthe investigators’ index,which doesn’t have a searchfacility, is under ‘Researchprograms’. A list of scientificresources is also locatedhere, although it took mesome time to track down oldfavourites such as the CancerGenome Anatomy Project.
The acclaimed CancerNetsite, which providesinformation on cancerdiagnosis and treatment, isnow housed in ‘Cancerinformation’. Types of cancerare listed alphabetically, andit’s easy to navigate betweeninformation for patients andthat for health professionals,but, again, the free-textsearch facility has gone.
What’s missing is a primerexplaining the rationale forthe reorganization, whichmaps the old resources ontothe new site and describesnew features. Without this,many of the NCI’s treasuresremain buried — to old andnew visitors alike.
Cath Brooksbank
WEB WATCH